Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

59.82
+0.38000.64%
Pre-market: 59.870.0500+0.08%04:50 EST
Volume:9.71M
Turnover:581.18M
Market Cap:121.39B
PE:-13.55
High:60.26
Open:59.43
Low:59.38
Close:59.44
Loading ...

HSBC Adjusts Price Target on Bristol-Myers Squibb to $56 From $58, Keeps Hold Rating

MT Newswires Live
·
28 Feb

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q4 Earnings?

StockStory
·
28 Feb

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 Feb

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
27 Feb

Bristol-Myers Squibb Company (BMY): Top Stock to Buy from Dividend Stock Portfolio For Income

Insider Monkey
·
27 Feb

Got $200? 2 Healthcare Stocks to Buy and Hold Forever

Motley Fool
·
26 Feb

Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage. -- Barrons.com

Dow Jones
·
25 Feb

Why Bristol-Myers Squibb Co (BMY) Went Up On Monday?

Insider Monkey
·
25 Feb

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Business Wire
·
25 Feb

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
25 Feb

Bloomsbury Publishing Announces Change in Voting Rights Structure

TIPRANKS
·
25 Feb

BUZZ-Bristol Myers rises after FDA accepts application for combo drug for colorectal cancer

Reuters
·
24 Feb

Bristol-Myers Squibb Shares up 2.7% After FDA Accepts Co's Marketing Application for Combo Drug for Type of Colorectal Cancer

THOMSON REUTERS
·
24 Feb

BRIEF-U.S. FDA Accepts Bristol Myers Squibb’S Supplemental BLA For Opdivo® Plus Yervoy®

Reuters
·
24 Feb

Bristol-Myers Squibb Colorectal Drug Accepted for Priority Review

MT Newswires Live
·
24 Feb

Bristol Myers Gets Speedy FDA Review of Opdivo/Yervoy Combo in Certain Colorectal Cancer Patients

Dow Jones
·
24 Feb